OrbiMed Advisors Buys $5.0M in Pre-Funded Warrants from Public Offering

summarizeSummary

OrbiMed Advisors, an institutional investor with a board seat, purchased $5.0 million worth of pre-funded warrants in Shattuck Labs' recent public offering, signaling strong confidence.

check_boxKey Events

• Significant Insider Purchase

  OrbiMed Advisors, an institutional investor with a board representative, acquired 1,250,000 pre-funded warrants.

• Value of Investment

  The purchase totaled approximately $5.0 million, representing about 1.4% of Shattuck Labs' market capitalization.

• Participation in Public Offering

  The warrants were acquired on June 11, 2026, as part of the company's recently closed public offering, where warrants were priced at $3.9999 each.

• Vote of Confidence

  This substantial investment by a director-affiliated entity signals strong conviction in the company's outlook, especially following recent positive clinical trial data and a dilutive capital raise.

auto_awesomeAnalysis

This Form 4 reports a significant investment by OrbiMed Advisors, an institutional investor with a board representative, in Shattuck Labs' recent public offering. The purchase of $5.0 million in pre-funded warrants at the offering price, representing about 1.4% of the company's market cap, indicates strong conviction following the company's positive Phase 1 clinical trial results and successful capital raise. This substantial insider participation provides a vote of confidence in the company's future prospects.